Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans

Britnell, Sara R.; Willets, Amy E.; Vanderman, Adam J.; Woodard, Catherine L.; Britt, Rachel B.

doi:10.1002/phar.1845

Cited by 7 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DAAs used to treat HCV infection and their metabolism, transporter effects, and potential for interactions with chemotherapy, targeted agents, and supportive care medications commonly used to treat cancer are outlined in Tables . For more detailed information, please refer to Lexicomp Online (http://hep-druginteractions.org; Lexicomp, Inc, Hudson, OH; November 2016) and medication package labeling.…”

Section: Potential Interactions Between Daas and Chemotherapy Targetmentioning

confidence: 99%

The oncologic burden of hepatitis C virus infection: A clinical perspective

Torres

Shigle

Hammoudi

et al. 2017

CA A Cancer J Clinicians

110

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection affects millions of people worldwide and is associated with cancer. Direct-acting antivirals (DAAs) have changed HCV treatment paradigms, but little is known about management of HCV infection in patients with cancer. The substantial burden of HCV infection in patients with cancer and the inconclusive evidence regarding detection and management of HCV infection in patients with cancer prompted us to review the literature and formulate recommendations. Patients for whom HCV screening is recommended included all patients with hematological malignancies, hematopoietic cell transplant candidates or patients with hepatocellular carcinoma (HCC). There is lack of consensus-based recommendations for the identification of other cancer patients but physicians may consider screening patients belonging to groups at heightened risk of HCV infection including persons born during 1945–1965 and those at high risk for infection. Patients with evidence of HCV infection should be assessed by an expert to evaluate liver disease severity, comorbidities associated with HCV infection, and treatment opportunities. DAA therapy should be tailored on the basis of patient prognosis, type of cancer, cancer treatment plan, and hepatic and virologic parameters. HCV-infected cancer patients with cirrhosis (or even advanced fibrosis) and those at risk for liver disease progression, especially patients with HCV-associated comorbidities, should have ongoing follow-up, regardless of whether there is a sustained virologic response, to ensure timely detection and treatment of HCC. HCV infection and its treatment should not be considered contraindications to cancer treatment and should not delay the initiation of an urgent cancer therapy.

show abstract

Section: Potential Interactions Between Daas and Chemotherapy Targetmentioning

confidence: 99%

The oncologic burden of hepatitis C virus infection: A clinical perspective

Torres

Shigle

Hammoudi

et al. 2017

CA A Cancer J Clinicians

110

View full text Add to dashboard Cite

show abstract

“…2,3 It has been speculated that HCV eradication could improve liver function, leading to a decreased warfarin dose-response. 1,4 If true, such a mechanism would result in persistent reduction of warfarin dose-response beyond antiviral treatment completion. If DDI is the only cause, the warfarin dose-response would eventually return to baseline after HCV treatment completion.…”

mentioning

confidence: 99%

Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin: Twelve-Week Post-treatment Follow-up

DeCarolis¹,

Chen²,

Westanmo³

2017

Ann Pharmacother

View full text Add to dashboard Cite

“…Pathophysiologically, cell-mediated immunity is responsible for the destruction of epithelial cells. Macrophages and CD8 T lymphocytes release a large number of cytokines that lead to the inflammation and subsequent death of epithelial cells [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Erythema Multiforme-Like Presentation in an Asymptomatic COVID-19 Patient

Tahir¹,

Souliman²,

Rosa³

et al. 2021

Cureus

View full text Add to dashboard Cite

In clinical practice, there are a lot of variations in disease manifestations. Diseases are constantly evolving, and one negative test cannot completely rule out a disease. Erythema multiforme (EM) is a common mucocutaneous disease that can be linked to a lot of etiologies, with the most common being herpes simplex virus (HSV) types 1 and 2, Mycoplasma pneumoniae, and the use of various drugs. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new virus, and traditionally it is not the first differential for EM eruptions. We report the case of a 52-year-old female patient with a history of multiple drug use, pneumonia-like symptoms, an initial negative viral panel for SARS-CoV-2, followed by a positive polymerase chain reaction (PCR) test, asymptomatic coronavirus disease 2019 (COVID-19) clinical course, and break-out of typical targetoid lesions of EM. Throughout her hospital stay, the patient maintained her oxygenation levels and improved clinically with steroids and symptomatic treatment. She regained her health and was counseled to quit smoking, alcohol, and opioid usage at the time of discharge from the hospital, and a regular follow-up with her primary care practitioner (PCP) was advised.

show abstract

Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans

Cited by 7 publications

References 12 publications

The oncologic burden of hepatitis C virus infection: A clinical perspective

The oncologic burden of hepatitis C virus infection: A clinical perspective

Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin: Twelve-Week Post-treatment Follow-up

Erythema Multiforme-Like Presentation in an Asymptomatic COVID-19 Patient

Contact Info

Product

Resources

About